Showing results (471-480 of 520) with videos related to

Sort By:
Pageof 52
Cell Reports|September 26, 2019
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor ResponsesAbhishek S Kashyap, Laura Fernandez-Rodriguez, Yun Zhao, et al.
Journal of Neurosurgery. Spine|April 4, 2025
Association between subaxial paraspinal muscle parameters and cervical vertebral bone quality in preoperative patientsArtine Arzani, Bruno Verna, Thomas Caffard, et al.
Clinical Lung Cancer|April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
Nature Immunology|February 19, 2020
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumorsHaiping Wang, Fabien Franco, Yao-Chen Tsui, et al.
Nature Communications|November 21, 2025
Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancerAnaïs Perrichet, Julie Lecuelle, Emeric Limagne, et al.
Spine|June 15, 2023
Decision-making Algorithm for the Surgical Treatment of Degenerative Lumbar Spondylolisthesis of L4/L5Lukas Schönnagel, Thomas Caffard, Jiaqi Zhu, et al.
ESMO Open|April 10, 2022
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trialsD König, S Schär, D Vuong, et al.
Science Translational Medicine|July 20, 2022
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunityNicole Kirchhammer, Marcel P Trefny, Marina Natoli, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 6, 2024
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage MelanomaKarlijn de Joode, Alfonso Rojas Mora, Ron H N van Schaik, et al.
Pageof 52